Bryn Pharma said today that it raised nearly $18 million in financing to fund U.S. approval and commercialization for its Bryn-NDS1C bidose epinephrine nasal spray device for treating anaphylaxis. The $17.5 million funding round was the company’s fourth completed financing series and it included $15 million from existing and new investors, while the remaining $2.5 […]
Bryn Pharma
Aptar Pharma’s two-dose nasal spray device to deliver epinephrine
Aptar Pharma has entered an agreement for Bryn Pharma to use Aptar’s Bidose (BDS) nasal device to deliver Bryn’s epinephrine nasal spray (BRYN-NDS1C). Crystal Lake, Ill.-based Aptar’s Bidose tech enables two-shot nasal drug delivery and will replace the need to carry two epinephrine auto-injectors, according to the companies. Last March, Aptar won FDA approval to […]